As such, it opens up opportunities to develop mutant specific NRF2 inhibitors, allowing tumor specific NRF2 inhibition while leaving wild type NRF2 in normal tissues to carry out its protective functions. This evidence concerns the gene NFE2L2 and neoplasm.